Dermatology specialist Valeant Pharmaceuticals International, Inc. continues to pack on mass and diversify its portfolio with the $8.7 billion acquisition of Bausch + Lomb Inc., ballooning its stake in the consumer eye-care space.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?